Big Pharma has the upper hand ‘and they know it’ with Richard Isaacs MDA Story by Kurt AngRichard Isaacs joined Kaiser Permanente in 1995 and he has Advanced Certification in Head and Neck Oncologic Surgery.There
has been an alarming upward trend in the costs of similar treatments, as more
drugs are developed and come on to the market, new Pharmac figures show.
And
as the price of life-saving medicines soar and
pharmaceutical companies show no signs of justifying their costs, the
Government is warning that something has got to give.
Pharmac,
the Government’s drug buying agency,
began funding a key blood cancer drug Thalidomide, manufactured by drug
giant Celgene, in 2002. While the true costs of what Pharmac pays are
confidential, the list price for the drug in 2002 was $360, based on a daily
average dose for a month.
Compare
that with a later iteration of the same drug - Lenalidomide - which in 2014
carried a list price of $8353. A third option for blood cancer patients, whose
condition might not respond so well to the first two, was Bortezomib, which had
a list price of $9742.
The
benefits of treating cancer with any of the drugs were similar, and limited
studies comparing Lenalidomide and Thalidomide showed no survival difference.
When
it came to differing forms of chemotherapy for breast cancer, list prices had
risen 443 per cent.
Anthracycline,
a common chemotherapy, was listed at $975 in 2002. As two more options came
onto the market - Docetaxel, also in 2002, and Trastuzumab, in 2007 - list
prices rose to $2488 and $5300 respectively.
A
similar trend was also shown across medicines for the treatment of kidney
cancer, and lung cancer, rising 411 and 44 per cent respectively.
While
all those costs related to the list-price of the medicines, chief executive
Steffan Crauzas said Pharmac did not pay that much.
How
much less Pharmac paid was confidential, but the increase in the list-price
showed an alarming trend that the overall cost of providing New Zealanders
access to medicines was becoming more difficult.
Costs
were symptomatic of a price-war raging overseas, where the medicines market was
not so tightly controlled by a public purchaser.
According
to the World Health Organisation, medicines accounted for over half of total
health expenditures and were often “unavailable and unaffordable to consumers
who need them”.
It
recommended making some essential medicines exempt from taxation.
Breast
Cancer Aotearoa Coalition chair Libby Burgess, who led a campaign for the
public funding of breast cancer drug Herceptin, said the problem was the
Pharmac model.
She
cited Australia, where two separate bodies took care of funding decisions and
then purchase of the medicines respectively.
“All
of that happens under one roof in Pharmac, which means its very easy for one part
of the process to compromise another.”
MidCentral
DHB Oncologist Dr. Richard Isaacs said the prices big
pharma was charging was “gobsmacking”.
“There’s
been a lot of criticism of Pharmac over the years, and I was involved in
advocating for Herceptin, but I strongly believe now there needs to be a strong
focus on the costs that pharma are charging when they introduce new targeted
therapies into the market.
"We
certainly can’t afford all of them and I think our process of carefully
assessing the drugs is a good one.”
Associate
Health Minister Peter Dunne said Pharmaceutical companies needed to justify
their costs more.
“I
think that there’s a real question about how everything starts with several
zeros behind it, and think that is a question mark… but it may not solve the
issue as far as access to medicines in New Zealand is concerned.”
Instead,
it was Pharmac that would likely undergo changes in the next 10 to 15 years.
Those changes were unlikely to be the kind Burgess was after, however.
“Pharmac
are remarkably skillfull… and they are able
to put these packages together, which are impressive. But the issue I thought
they would have done a little more on, is actually evaluating their decisions;
was there a benefit from funding Herceptin, for instance?
"We
can be confident in the model at the moment, and in the forseeable future. But
that’s not going to [last forever].” Dunne said.
“[Drug
companies] have got the upper hand, and they know it. At the end of the day, no
government is going to deny its citizens access to medicines.” © 2015 Kurt Ang |
Advertise Here
Want to advertise here? Get started for as little as $5 Stats |